Statistics

Total Visits

Views
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer35

Select a period of time:

Number of views in the range

Views
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer7

Views

Views
May 20252
June 20251
July 20250
August 20250
September 20252
October 20250
November 20252
Download CSV file
 untranslated
 untranslated

Top country views

Views
Brazil4
United States2
Singapore1
 

Top cities views

Views
Dallas2
Belo Horizonte1
Canaã dos Carajás1
Concórdia1
Franca1